Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington’s chorea: a survey of neurologists and psychiatrists

Résumé fourni par la source

BACKGROUND: This study assessed neurologists' and psychiatrists' experience with and perceptions of tetrabenazine (TBZ) when treating patients with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea. RESEARCH DESIGN AND METHODS: Neurologists and psychiatrists from Australia and Israel who manage TD, and neurologists from Australia, Israel, and South Korea who manage HD-related chorea, answered 20-minute anonymous online questionnaires. RESULTS: = 20), most (61%; 80%) were moderately satisfied with TBZ for treatment of TD/HD-related chorea, some were dissatisfied (23%; 10%), and only 17% and 10% were very/extremely satisfied. Additionally, 18% and 25% reported that they were often/almost always unable to titrate TBZ to optimal doses because of side effects and 24% and 15% reported that side effects often/almost always led to TBZ discontinuation. CONCLUSION: Although most physicians were moderately satisfied with TBZ, they also reported that TBZ side effects prevented reaching optimal clinical effectiveness and often led to discontinuation, suggesting a need for additional effective treatment options with favorable benefit-risk profiles for TD and HD-related chorea.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.